



**Eris**

ERIS LIFESCIENCES LIMITED

# COMPANY PROFILE

---

# Brief Profile

**Eris Lifesciences Ltd**

**Eris Lifesciences Pvt Ltd** is fastest growing super specialty focused pharmaceutical company and is engaged in manufacturing, marketing and selling of branded generics across the country. It mainly focuses on Cardiology, Diabetology, Endocrinology, Gastroenterology, ENT, Orthopedics, Pediatrics and Gynecology segments and offer world class products across these therapy segments.

Eris Lifesciences founded by Mr Amit Bakshi and team in 2007 is one of the fastest growing companies within the chronic and acute categories of the Indian Branded Formulations market such as: cardiovascular; anti-diabetes; vitamins; gastroenterology and gynaecology. The company's focus has been on developing, manufacturing and marketing products which are linked to lifestyle related disorders that are chronic in nature and are treated by superspecialist and specialist doctors. Eris features amongst the Top 30 companies in the Indian Branded Formulations Market.

The company's core commitment is towards improving health care outcomes and adding value for all its stakeholders including patients, doctors, regulators, employees and business partners. The company is making ongoing efforts to innovate its products to bring the best clinical practices in health care industry to its customers.

The company's product portfolio is primarily focused on therapeutic areas which are treated by super-specialist and specialist doctors such as Diabetologists, Endocrinologists, Cardiologists, Gastroenterologists, and Neurologists.

Business area of the company

The company develops, manufactures and commercializes branded pharmaceutical products in select therapeutic areas within the chronic and acute categories of the IPM, such as: cardiovascular; anti-diabetics; vitamins; gastroenterology; and anti-infectives. Its focus has been on developing products in the chronic and acute category which are linked to lifestyle related disorders.



## History and milestones

- 2007: Incorporation of the company.
- 2007: Launched “Eris” division focused on cardiology and diabetes segment.
- 2008: Launched “Nikkos” division focused on gastroenterology and orthopedics segment.
- 2009: Launched “Adura” division focused on cardiology and diabetes segment.
- 2011: Launched “Montana” division focused on gynecology and pediatrics segment.
- 2012: Launched “Inspira” division focused on cardiology segment.
- 2014: Launched “Victus” division focused on anti-diabetes segment.
- 2014: Set up Assam Facility by the company.
- 2015: Launched “Eris 2” division focused on pain management segment.
- 2016: Acquired 40 registered and unregistered trademarks from Amay Pharmaceuticals Private Limited (now, Aprica Pharmaceuticals Private Limited).
- 2016: Acquired 100.00% of the outstanding equity shares of Aprica Healthcare Private Limited.
- 2016: Acquired 75.48% of the outstanding equity shares of Kinedex Healthcare Private Limited.
  
- 2017: Acquired the trademarks ‘UNION’, ‘REUNION’ and ‘BON UNION’.
- 2017: Eris acquires 40 trademarks from Amay Pharma
- 2017: Eris acquires Pune based UTH Healthcare.
- 2018: Eris entered into a distribution agreement with India Medtronic Private Limited.
- 2019: Eris Lifesciences acquires trademark Zomelis from Novartis AG for \$13 mn.
- 2019: Eris partners with Pharmanutra S.P.A of Italy for Sideral.





**Snapshot - Eris Lifesciences Ltd. - Consolidated**


Registered Office: Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off S B R, Ahmedabad, 380054, Gujarat

Eris Lifesciences Pvt Ltd is fastest growing super speciality focused pharmaceutical company and is engaged in manufacturing, marketing and selling of branded generics across the country. It mainly focuses on Cardiology, Diabetology, Endocrinology, Gastroenterology, ENT, Orthopedics, Pediatrics and Gynecology segments and offer world class products across these therapy segments.

**Company Details**

Industry	Pharmaceuticals & Drugs
Chairman	Amit Indubhushan Bakshi
Managing Director	Amit Indubhushan Bakshi
Company Secretary	Milind Talegaonkar
ISIN	INE406M01024
Bloomberg Code	ERIS IN
Reuters Code	ERIS.BO

**Price Vs Sensex Chart**



**Key Market Indicators (Consolidated)**

Latest Date	27-Dec-2022
Latest Price (Rs)	653.75
Previous Close (Rs)	663.90
1 Day Price Var%	-1.53
1 Year Price Var%	-4.87
52 Week High (Rs)	782.50
52 Week Low (Rs)	600.50
Beta	0.4737
Face Value (Rs)	1.00
Industry PE	34.99
Industry BV	3.45
TTM Period	202209
TTM EPS(Rs)	29.12
TTM CEPS(Rs)	35.33
Price/TTM CEPS(x)	18.50
TTM PE (x)	22.45
Price/BV(x)	4.39
EV/TTM EBIDTA(x)	17.36
EV/TTM Sales(x)	6.12
Dividend Yield%	0.92
MCap/TTM Sales(x)	6.02
Latest Book Value (Rs)	149.05
Market Cap (Rs. In Crores)	8,890.39
EV (Rs. In Crores)	9,036.32
[Latest no. of shares (Rs. In Crores)]	13.60

**[Share Holding Pattern as on 202209]**

[Promoter No of shares (In Crores)]	7.11
Promoter %	52.29
FII No of Shares (In Crores)	2.09
FII %	15.39
Total No of Shares (In Crores)	13.60
Free Float %	47.71

**Inc/Exp Statement(Consolidated)**

Description	(Rs in Crores)				
	202203	202103	202003	201903	201803
Net Sales	1347.04	1211.86	1074.06	982.16	855.6
Total Income	1373.14	1220.57	1090.07	1013.86	882.01
Total Expenditure	862.02	781.11	706.17	637.08	533.49
PBIDT	511.12	439.46	383.9	376.77	348.52
PAT	405.79	355.14	296.51	291.15	294.98
Dividend %	601	550	287		
Adj. EPS(Rs)	29.88	26.16	21.84	21.15	21.39

**Assets and Liabilities (C) as on 202209(U)**

(Rs in Crores)	
Share Capital	13.6
Reserve	2013.34
Share Holder's Funds	2026.94
Long Term Debt - Calc	83.44
Short Term Debt - Calc	132.57
Total Debt - Calc	216.01
Net Block	1426.15
Long term Investments	4.22
Short term investments	0
Total Investments	4.23
Cash and Bank Bal	70.08
Net Current Assets	255.59

**Quarter On Quarter (Consolidated)**

Particulars	(Rs in Crores)				
	202209	202206	Q on Q Var%	202109	Y on Y Var%
Net Sales	455.33	392.05	16.14	353.34	28.86
Total Expenditure	309.06	269.38	14.73	219.85	40.58
PBIDT (Excl OI)	151.446	129.205	17.21	139.822	8.31
PAT	119.38	93.08	28.26	118.39	0.84
PBIDTM% (Excl OI)	32.89	32.42	1.45	38.88	-15.41
PBIDTM%	34.01	33.1	2.75	40.82	-16.68
PATM%	25.92	23.35	11.01	32.92	-21.26
Adj. EPS(Rs)	8.85	6.96	27.16	8.71	1.61



Top Holdings as on 202209		
Name	Category	Holding %
Amit Indubhusan Bakshi	Promoters	40.27
Emerald Investments Limited	Non - Promoters	7.58
Uti Flexi Cap Fund	Non - Promoters	4.88
Inderjeet Singh Negi	Promoters	4.37
Rajendrakumar Rambhai Patel	Promoters	4.37
Kaushal Kamleshkumar Shah	Promoters	3.29
Aditya Birla Sun Life Trustee Private Limited A/C Aditya Birla Sun Life Equity Hybrid '95 Fund	Non - Promoters	1.69

Latest Events [BC, Bonus, AGM, Split & Rights Only]
No Records Found

Peer Group Comparison					(Rs in Crores)
Company Name	Eris Lifesciences	FDC	Indoco Remedies	Morepen Laboratories	Sequent Scientific
Year End	202203	202203	202203	202203	202203
Net Sales	1347.04	1527.92	1540.75	1546.83	1412.82
PBIDT	511.12	329.78	332.96	156.77	120.25
PAT	405.79	216.16	154.8	101.68	45.06
Adj. EPS(Rs)	29.88	12.82	16.8	2.13	1.66
PBIDTM%	36.64	20.96	21.61	10.14	8.51
PATM%	29.09	13.74	10.05	6.57	3.19
ROCE%	25.29	15.78	23.33	24.86	7.06
ROE%	23.33	11.71	18.5	21.79	6.6
<b>TTM Ratios</b>	27-Dec-2022	27-Dec-2022	27-Dec-2022	27-Dec-2022	27-Dec-2022
Latest EPS(Rs)	29.12	10.17	17.55	1.08	0.33
Latest CEPS(Rs)	35.33	12.42	25.48	1.62	2.45
Price/TTM CEPS(x)	18.5	21.88	15.47	22.83	35.29
TTM PE (x)	22.45	26.72	22.46	34.21	260.1
Price/BV(x)	4.39	2.37	3.74	2.57	2.92
EV/TTM EBIDTA(x)	17.36	16.83	12.3	18.38	29.76
EV/TTM Sales(x)	6.12	2.77	2.5	1.27	1.75
Dividend Yield%	0.92	0	0.57	0	0
MCap/TTM Sales(x)	6.02	2.78	2.34	1.29	1.52
Latest Book Value (Rs)	149.05	114.55	105.29	14.41	29.57

Company News	
Date	News
09-Nov-2022	Eris Lifesciences informs about analyst meet
20-Oct-2022	Results Commentary
24-Sep-2022	Eris Lifesciences informs about disclosure
19-Sep-2022	Eris Lifesciences informs about institutional investor meetings
03-Sep-2022	Eris Lifesciences informs about investor meet

Latest Events		
Date	Events	Details
13-Oct-2022	Clarification	This is with reference to your email dated October 13, 2022 seeking clarification for significant increase in the Volume of our Security across the Exchanges. In this regards, we wish to inform you that all the material information / announcement that may have bearing on the operations / performance of the Company which include all the necessary disclosures in accordance with regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and under insider trading regulation, have always been disclosed by the Company within stipulated time and the same is available in public domain. There is no pending information or announcements which have a bearing on increase in price/volume of security of the Company.
11-Oct-2022	Board Meeting	Quarterly Results
05-Aug-2022	Board Decision	Inter alia, approved Declaration of interim dividend of Rs. 7.35/- (at the rate of 735%) on each fully paid-up equity share of Re. 1/- for the Financial Year 2022-2023
02-Aug-2022	Dividend Announcement	Quarterly Results & Interim Dividend
29-Jul-2022	Board Meeting	Quarterly Results & Interim Dividend





**To get more updates like this join our WhatsApp Group**



**We, at Sukhanidhi, are on a massive mission to help 1000+ individual DIY investors create sustainable wealth over the long term to secure their retirement needs. We understand that the working hours and years of an individual will decrease with age and that everyone requires an income stream to maintain a certain lifestyle as they get older.**

**We are waiting for you to join the mission.**

**What are you waiting for?**

